How Is Terlipressin Stored? Stability, Per the Label and Research

Who handles terlipressin, and where it is stored

Terlipressin is a prescription medicine administered by specialist clinicians in a clinical setting, typically a hospital ward, an infusion area, an operating room or a critical care unit. Because of that, storage is managed inside hospital pharmacy and clinical supply systems rather than by an individual at home. Vials or ampoules are received, logged, held under the conditions stated on the manufacturer labeling, and dispensed to the treating team. Any question about a specific product, a specific indication or an individual treatment plan belongs with the treating specialist team; talk to your prescriber.

This page is for educational purposes only and is not medical advice; consult a licensed physician for any question about diagnosis, treatment or medicines. It describes what product labeling and published literature report about storage and stability, and it does not provide preparation, reconstitution, administration or dosing directions of any kind.

Approved use, at label level

In the United States, a terlipressin product is approved for adults with hepatorenal syndrome with rapid reduction in kidney function, and the approved wording sits in that product's prescribing information. Terlipressin products are also marketed in other countries under different labeling, and the approved indications are not identical across regions. Any use outside the indication approved in a given country is investigational in that setting, and discussion of such use belongs with the prescribing clinician rather than with a general education page.

What product labeling describes about storage

Storage information for a medicine sits in a defined section of its labeling, and that section is the controlling source for the specific carton in hand. For terlipressin the practical point is that presentations differ. Some terlipressin products are supplied as a lyophilized powder in a single-dose vial, while others have been supplied as a ready-made solution in ampoules or pre-filled presentations, and the storage statement is not the same for each.

Labeling for terlipressin solution presentations in several European markets has described refrigerated storage in the range of 2°C to 8°C, with the product kept in its original carton until use. Labeling for lyophilized powder presentations has described storage at controlled temperatures stated on the carton, again with the original packaging retained until the pharmacy prepares the product. Because the numbers and wording differ between manufacturers, between presentations and between regulatory jurisdictions, the only statement that applies to a given vial is the one printed in that product's own labeling and carton text.

Label storage sections also carry three elements that are easy to overlook. The first is the excursion statement, which describes whether brief departures from the nominal temperature range are permitted. The second is the expiry date, which applies to the unopened product held under the stated conditions. The third is the in-use or after-preparation statement, which describes how long a prepared solution is considered suitable and under what conditions, and which is written for the pharmacy and clinical staff who prepare it.

What stability research has reported

Separate from labeling, researchers have published laboratory work on terlipressin stability. A 2020 report in Scientific Reports investigated the stability of reconstituted terlipressin infusion solutions intended for use in hepatorenal syndrome, and the study was framed around whether prepared infusion solutions remain chemically suitable across a storage period rather than around any individual patient's treatment (PMID 33273555). That investigation is the most directly relevant published stability work for terlipressin infusions, because continuous infusion delivery depends on a prepared solution remaining intact in the syringe or bag for the duration of administration (PMID 33273555).

Stability studies of this kind generally follow a common structure. Solutions are prepared under controlled conditions, held at defined temperatures, sampled at set time points and analysed by chromatographic methods that separate the intact peptide from degradation products. The 2020 Scientific Reports investigation applied that general approach to reconstituted terlipressin infusions and reported results in terms of retained peptide content over the tested storage interval (PMID 33273555).

Why analytical method quality matters to stability claims

A stability statement is only as good as the assay behind it, because the assay has to distinguish intact peptide from breakdown products. Work published in The Analyst in 2026 described a rapid and harmonized analytical workflow for determining peptidic and non-peptidic agents in dried and liquid blood matrices, illustrating how much attention peptide quantification requires in terms of sample handling, matrix effects and method validation (PMID 42328738). The same methodological care underlies formulation stability testing, where small analytical differences change how a result is interpreted (PMID 42328738).

In-use stability and the shift toward continuous infusion

Interest in how long a prepared terlipressin solution stays intact grew alongside clinical interest in continuous infusion delivery. A narrative review published in Pharmacotherapy in 2025 compared continuous infusion and intermittent bolus administration strategies for terlipressin in hepatorenal syndrome with acute kidney injury, and described the practical and clinical considerations that separate the two approaches (PMID 41314419). A phase 2 trial reported in Liver Transplantation in 2025 evaluated the safety and efficacy of continuous infusion terlipressin in patients with decompensated cirrhosis and refractory ascites (PMID 40272365). A randomized controlled trial published in the Journal of Clinical Gastroenterology in 2026 compared clinical outcomes with continuous infusion versus bolus terlipressin in patients with acute variceal hemorrhage (PMID 41264338).

Infusion-based delivery has also been studied in other critical care contexts. A randomized trial published in Liver International in 2017 compared terlipressin with noradrenaline in patients with cirrhosis and septic shock (PMID 27633962), and a 2026 report in the Journal of Clinical Medicine described intraoperative terlipressin during liver transplantation in relation to vasoactive requirements and postoperative troponin release (PMID 42074720). Each of those settings involves a solution prepared by hospital staff and delivered over time, which is exactly the scenario an in-use stability statement addresses (PMID 41314419).

Degradation, and what changes it

Peptides in solution are affected by temperature, pH, oxygen exposure, light, adsorption to container surfaces and the choice of diluent. For terlipressin specifically, published evidence on prepared infusion stability comes from the 2020 Scientific Reports investigation, which was designed around the storage interval and conditions relevant to continuous infusion in hepatorenal syndrome (PMID 33273555). Where labeling and a published study appear to differ, the labeling governs clinical practice, because it is the regulated statement tied to the specific manufactured product.

Formulation chemistry is also an active research area. A 2024 report in ACS Pharmacology and Translational Science described a long-circulating 1,18-octadecanedioic acid terlipressin conjugate, a modified molecule designed with altered circulation characteristics (PMID 38751631). That conjugate is a distinct investigational entity and its properties say nothing about how an approved terlipressin product should be stored (PMID 38751631).

Which source says what

General peptide storage principles versus a hospital medicine

Broad principles about peptide storage, including cold chain handling, light protection and the behaviour of lyophilized versus solubilised peptides, are summarised in the PeptideU guide to how peptides are stored. Those general principles help explain why labeling says what it says, but they do not override a product label and they do not translate into any at-home practice for a medicine that is administered by specialists in a clinical setting. For terlipressin, the operative documents are the prescribing information for the exact product and the hospital pharmacy procedures built around it.

What the literature does not settle

Published stability work on terlipressin is limited in volume, and the available investigation focused on reconstituted infusion solutions in the hepatorenal syndrome context rather than on every possible diluent, container or temperature combination (PMID 33273555). Clinical research continues to compare delivery strategies, including the 2025 phase 2 continuous infusion trial in decompensated cirrhosis with refractory ascites (PMID 40272365) and the 2026 randomized comparison of continuous infusion and bolus delivery in acute variceal hemorrhage (PMID 41264338). As those strategies are studied further, in-use handling questions are likely to receive more attention, and the narrative review in Pharmacotherapy framed those operational differences explicitly (PMID 41314419). Until labeling changes, the carton and the prescribing information remain the reference point, and clinical questions belong with the prescribing clinician.

References

• An investigation of reconstituted terlipressin infusion stability for use in hepatorenal syndrome (Scientific Reports, 2020)
• Terlipressin Administration Strategies in Hepatorenal Syndrome-Acute Kidney Injury: A Narrative Review of Continuous Infusion and Intermittent Bolus Approaches (Pharmacotherapy, 2025)
• Safety and efficacy of continuous infusion terlipressin (BIV201): A phase 2 trial in patients with decompensated cirrhosis and refractory ascites (Liver Transplantation, 2025)
• Clinical Outcomes of Terlipressin Using Continuous Infusion Versus Bolus in Patients With Acute Variceal Hemorrhage: A Randomized Controlled Trial (Journal of Clinical Gastroenterology, 2026)
• A randomized trial comparing terlipressin and noradrenaline in patients with cirrhosis and septic shock (Liver International, 2017)
• Intraoperative Terlipressin During Liver Transplantation Is Associated with Reduced Vasoactive Requirements and Lower Postoperative Troponin Release (Journal of Clinical Medicine, 2026)
• Long-Circulating Vasoactive 1,18-Octadecanedioic Acid-Terlipressin Conjugate (ACS Pharmacology and Translational Science, 2024)
• Rapid and harmonized analytical workflow for the determination of peptidic and non-peptidic doping agents in dried and liquid blood matrices (The Analyst, 2026)